Physician profile
Carolyn L Ebert
NPI 1588878201
$1,520.01
in general payments reported to CMS, 2019-2025
19 companies · $655 in 2025
The $655 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2022: $20.04 · 2023: $239 · 2024: $503 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $288.78 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $239.39 | 2023-2025 | Repatha, Otezla, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.28 | 2025 | Caplyta |
| Lilly USA, LLC | $129.40 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $106.04 | 2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $105.91 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $102.84 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $98.39 | 2025 | Rexulti |
| Astellas Pharma US INC | $69.95 | 2024-2025 | Veozah |
| Radius Health, INC. | $49.29 | 2023-2025 | Tymlos |
| Abbvie INC. | $41.09 | 2023-2025 | Vraylar |
| Phadia US INC. | $30.95 | 2023-2024 | Immunocap |
| Alvogen INC | $20.06 | 2025 | Teriparatide |
| Pfizer INC. | $20.04 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.80 | 2024 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $16.82 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $13.98 | 2025 | Airsupra |
| Endogastric Solutions, INC | $9.43 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Ebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.